NAVB / Why Is Navidea Biopharmaceutical (NAVB) Stock Down 13% Today?

Navidea Biopharmaceutical (NYSEMKT: NAVB ) stock is falling on Monday after the biopharmaceutical company got a major delisting warning. The NYSE Ame more_horizontal

Navidea Biopharmaceuticals Inc. NAVB, -2.38% announced Friday that it had rejected an unsolicited ProPhase Labs Inc. PRPH, +0.08% offer for certain Na more_horizontal

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q4 2022 Earnings Conference Call March 22, 2023 5:00 PM ET Company Participants Michael Rosol - SVP & Ch more_horizontal

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q3 2022 Earnings Conference Call November 15, 2022 5:00 PM ET Company Participants Michael Rosol – Chi more_horizontal

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q2 2022 Earnings Conference Call September 8, 2022 4:00 PM ET Company Participants Michael Rosol – CMO more_horizontal

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the developme more_horizontal

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q1 2022 Results Conference Call May 12, 2022 5:00 PM ET Company Participants Michael Rosol - CMO Erika E more_horizontal

Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2021 Results - Earnings Call Transcript more_horizontal